News +++ News
All you need to know as Medical Device Manufacturer under EU legislation:
New „Step by Step Guide Implementation Model for Medical Devices Regulation“ and „Factsheet for Manufacturers“ are now available! ... read more
OVERVIEW OF EUROMCONTACT WORKSHOPS IN 2018:
PREPARE FOR IMPLEMENTATION OF THE MEDICAL DEVICES REGULATION
26th September 2018
Clinical Aspects of the Medical Devices Regulation ... read more.
15th October 2018
Post-market surveillance and post-market clinical follow-up ... read more.
Q 3 2018 – Eudamed
Q 4 2018 – Notified Bodies
Workshops include presentations by European Commission, Competent Authorities of Member States; Notify Bodies and Industry leaders, followed by question and answer session with speakers.
BAUSCH + LOMB ANNOUNCES LICENSING AGREEMENT WITH TANGIBLE SCIENCE FOR USE OF TANGIBLE HYDRA-PEG CUSTOM CONTACT LENS COATING TECHNOLOGY BRIDGEWATER, N.J., June 25, 2018
Bausch + Lomb, a leading global eye health company, today announced that it has entered into a worldwide licensing agreement with Tangible Science, LLC, a company whose mission is to create technologies that improve the contact lens wearing experience. As part of the agreement, Bausch + Lomb will offer the Tangible Science Hydra-PEG® advanced contact lens coating technology for use with several of its Boston® gas permeable (GP) materials including Boston XO®, Boston XO2®, Boston EO®, and Boston ES®.
Please contact us for further details.
MDD – MDR
Current MDD – New MDR
In this section our own MDR expert – Alan Bennett – provides a short summary of how the MDR Lounge, located at the Boston® Materials booth at the recent EFCLIN conference in Dubrovnik, heralded the beginning of the journey towards MDR implementation in partnership with the Custom Labs who place product onto the EU market. Read more...
What is changing and what are the change drivers?
The Future of Vision Correction is Here
Should eye care professionals be obligated to inform patients about all alternative options to correct myopia?
Do you feel it is our role to support the communication about industry advancements like OrthoK?
Would it be negligent not to offer myopia management to patients?
Our introduction video is available with subtitles in the langauages below: